StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck ProQuad / M-M-R II / Varivax by Year

ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

Merck ProQuad / M-M-R II / Varivax: -2.0% in FY2025, down 7.0 pts from a year earlier.

Latest, FY2025
-2.0%
Period ended Dec 31, 2025
Change on a year earlier
-7.0 pts
5.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below

Where the FY2025 figure comes from

“|| ProQuad/M-M-R II/Varivax | 539 | 609 | 684 | 619 | 2,451 | 570 | 617 | 703 | 594 | 2,485 | 4 | 3 | -1 | -2”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 2025-2.0%-7.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 20245.0%–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗

Cite this data

StockData. (2026). Merck ProQuad / M-M-R II / Varivax (%), annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-proquad-mmr-varivax-ww-exfx-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.